On the other hand, the HER2-positive breast cancer cell line, SKBR3, which demonstrated the highest sensitivity towards individual drugs at 24 h, had the lowest sensitivity and synergism in the sequential treatment regimen. The gene discussed is ERBB2; the disease is breast cancer.